14 Effects on rating scales were expressed as standardized mean differences (SMDs, in the event of different outcomes in aggregated trials) or mean differences (same outcome in every clinical trial), as appropriate for the comparison, with 95% confidence intervals (CIs).
Efficacy analyses were performed on the primary per-protocol population in each trial (as appropriate for non-inferiority studies), and analyses of BMD included the eligible subset of women for whom data were available at both screening and final visit.
At the start of the interviews, participants were encouraged to provide their views and perspectives on existing patient information leaflets for clinical trials and discuss their experiences of participating in clinical trials or reviewing clinical trial information, as appropriate.
Awareness of trial influences behaviour: All participants reported that they viewed the trial design as appropriate because awareness of participation in the trial could have of itself influenced their own or others behaviour, which could have biased the trial findings.
Participants whose plantar warts had not cleared were treated as censored, and we calculated their duration in the trial from their date of trial exit, date of last available assessment, or the 183 days to trial cessation, as appropriate.
In addition to the adjustment for baseline imbalance from the trial applied to pancreatic function (endocrine and exocrine), baseline adjustment was applied to one other trial estimate as appropriate: the utility scores.
Janssen Biotech, Inc. (Horsham, PA) provided infliximab, active comparator (AZA in the SONIC trial), and placebo (as appropriate) for intravenous infusion.
For each trial we extracted, as appropriate, the details of the intervention on to a standardised data sheet listing the 21 recommendations derived from the qualitative review.
After three meetings (2003 to early 2004), five trials were identified as appropriate for integration into the database on the committee's recommendations.
This differential index (in%) was calculated for the last acquisition trial (6th trial), as it constitutes an appropriate measure of the discrimination reached at the end of conditioning, and for the retention test.
The regression analyses in our paper rely entirely on the variation in treatment status induced by the experimental design of the trial, and thus are just as appropriate analytically as the simple "treatment minus control" differences that the Cochrane authors focus on.
